Last reviewed · How we verify
Sugammadex Injectable Product
Sugammadex is a selective relaxant binding agent that encapsulates and inactivates steroidal neuromuscular blocking agents, rapidly reversing neuromuscular blockade.
Sugammadex is a selective relaxant binding agent that encapsulates and inactivates steroidal neuromuscular blocking agents, rapidly reversing neuromuscular blockade. Used for Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery, Reversal of deep neuromuscular blockade in anesthetized patients.
At a glance
| Generic name | Sugammadex Injectable Product |
|---|---|
| Sponsor | Regina Elena Cancer Institute |
| Drug class | Selective relaxant binding agent |
| Target | Steroidal neuromuscular blocking agents (rocuronium, vecuronium) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Sugammadex works by forming a tight 1:1 complex with steroidal neuromuscular blocking drugs (such as rocuronium and vecuronium), effectively removing them from the neuromuscular junction and plasma. This encapsulation rapidly restores neuromuscular function without requiring acetylcholinesterase inhibitors. The drug is particularly useful for rapid reversal of deep neuromuscular blockade in anesthesia.
Approved indications
- Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery
- Reversal of deep neuromuscular blockade in anesthetized patients
Common side effects
- Nausea
- Vomiting
- Headache
- Hypotension
- Tachycardia
Key clinical trials
- The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery (PHASE4)
- Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection (PHASE4)
- Sugammadex v.s. Neostigmine/Glycopyrrolate (NA)
- Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery (PHASE4)
- Minimal Flow Anesthesia and Infection Risk (NA)
- Perioperative Respiratory Adverse events_sugammadex (PHASE4)
- Pharmacokinetic-pharmacodynamic Analysis of Sugammadex in Children (PHASE2)
- Pharmacokinetic-pharmacodynamic Analysis of Sugammadex for Conventional Reversal in Children (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sugammadex Injectable Product CI brief — competitive landscape report
- Sugammadex Injectable Product updates RSS · CI watch RSS
- Regina Elena Cancer Institute portfolio CI